Key result
Cisplatin and etoposide combination chemotherapy was associated with the development of paroxysmal supraventricular tachycardia in a 60-year-old woman with squamous lung carcinoma.
Case Report (n=1)
Cisplatin and etoposide combination chemotherapy may induce paroxysmal supraventricular tachycardia, suggesting caution in patients with underlying cardiac disease.
Answers are grounded in this paper and cite their sources.
Suggests possible arrhythmia risk with cisplatin-etoposide; hypothesis-generating and should not yet change practice.
We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed paroxysmal supraventricular tachycardia during cisplatin and etoposide combination chemotherapy. Cisplatin toxicity on cardiac electrical activity is discussed. This observation might suggest caution when cisplatin is used in patients with cardiac disease or pretreated with other potential cardiotoxic antineoplastic agents.
No takes yet. Share an insight, caveat, or question.
Fassio et al. (2009) conducted a case report in Squamous lung carcinoma (n=1). Cisplatin and etoposide combination chemotherapy was evaluated on Paroxysmal supraventricular tachycardia. Cisplatin and etoposide combination chemotherapy was associated with the development of paroxysmal supraventricular tachycardia in a 60-year-old woman with squamous lung carcinoma.
Synapse has enriched 10 related papers. Consider them for comparative context: